Bacteria in Tumors Could Help Personalize Colorectal Cancer Treatment

The presence of Fusobacterium bacteria in tumors could become a key tool for personalizing treatment in patients with early-stage colorectal cancer, according to results from the FUSOMAP multicenter project led by the Molecular Oncology Group at Vall d'Hebron Institute of Oncology (VHIO). This discovery enables clinicians to identify which patients may benefit most from specific therapeutic approaches based on their tumor's bacterial composition. By understanding the role of Fusobacterium in colorectal tumors, researchers can develop more targeted treatment strategies that improve outcomes and reduce unnecessary interventions. This advancement represents an important step toward precision medicine in colorectal cancer care.